» Articles » PMID: 16914872

Segregation of a Missense Mutation in the Amyloid Beta-protein Precursor Gene with Familial Alzheimer's Disease

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2006 Aug 18
PMID 16914872
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

In 1991 we described a missense mutation in the amyloid beta-protein precursor (AbetaPP) gene in two familial Alzheimer's disease (FAD) kindreds. This gene encodes the amyloid beta peptide deposited in senile plaques in AD. We made four predictions based upon these results: 1. Other FAD kindreds would be identified with AbetaPP mutations; 2. FAD is genetically heterogeneous; 3. Abeta deposition is central to the pathogenesis of AD and 4, Regulatory variants in the AbetaPP gene lead to late onset AD. In the ensuing years substantial evidence has accrued in support of these predictions. Nineteen mutations in the AbetaPP gene have been reported. These mutations have all been shown to alter AbetaPP processing or Abeta fibrillogenesis, leading to early Abeta deposition. Furthermore, mutations in the genes encoding presenilin 1 and presenilin 2, that cause FAD, also lead to changes in AbetaPP processing and Abeta deposition. Together these observations strongly support the hypothesis that Abeta deposition is central to AD pathogenesis. Suprisingly, the fourth prediction, that variation in AbetaPP expression may predispose to late onset AD, has not been rigorously tested, despite the fact that overexpression of AbetaPP is sufficient to cause dementia and AD neuropathology in Down Syndrome.

Citing Articles

Association of gene polymorphisms with susceptibility to Alzheimer's disease in an Iranian population.

Khalili-Moghadam F, Nejad J, Badri T, Sadeghi M, Gharechahi J Heliyon. 2024; 10(18):e37556.

PMID: 39309779 PMC: 11416268. DOI: 10.1016/j.heliyon.2024.e37556.


The Role of Non-coding RNAs in Alzheimer's Disease: Pathogenesis, Novel Biomarkers, and Potential Therapeutic Targets.

Saleh O, Albakri K, Altiti A, Abutair I, Shalan S, Mohd O CNS Neurol Disord Drug Targets. 2023; 23(6):731-745.

PMID: 37211844 DOI: 10.2174/1871527322666230519113201.


Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease.

Wang B, Zhong X, Fields L, Lu H, Zhu Z, Li L J Am Soc Mass Spectrom. 2023; 34(3):459-471.

PMID: 36745855 PMC: 10276618. DOI: 10.1021/jasms.2c00332.


Cell type-specific histone acetylation profiling of Alzheimer's disease subjects and integration with genetics.

Ramamurthy E, Welch G, Cheng J, Yuan Y, Gunsalus L, Bennett D Front Mol Neurosci. 2023; 15:948456.

PMID: 36683855 PMC: 9853565. DOI: 10.3389/fnmol.2022.948456.


Biomarkers for dementia in Latin American countries: Gaps and opportunities.

Parra M, Orellana P, Leon T, Victoria C, Henriquez F, Gomez R Alzheimers Dement. 2022; 19(2):721-735.

PMID: 36098676 PMC: 10906502. DOI: 10.1002/alz.12757.